Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages

  Nikiforova, Marina N ^a   Wald, Abigail I ^a   Roy, Somak ^a   Durso, Mary Beth ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CONTROLLED STUDY; CTNNB1 GENE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; FINE NEEDLE ASPIRATION BIOPSY; FROZEN SECTION; GENE FREQUENCY; GENE SEQUENCE; GENE TARGETING; GNAS GENE; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE RAS; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RET GENE; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; TISSUE FIXATION; TP53 GENE; TSHR GENE; TUMOR DIFFERENTIATION; TUMOR GENE;

ADENOCARCINOMA, FOLLICULAR; BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; NEOPLASMS; POINT MUTATION; REPRODUCIBILITY OF RESULTS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84887472968     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2292     Document Type: Article

References (58)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295: 2164-2167.
2. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18: 1-7.
3. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fineneedle aspirate cytology. Thyroid. 2006;16: 47-53.
4. Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000). Eur J Cancer. 2007;43: 891-900.
5. Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med. 1992;93: 359-362.
6. Gharib H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract. 2004;10: 31-39.
7. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411- 3417.
8. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941- 1946.
9. Greaves TS, Olvera M, Florentine BD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000; 90: 335-341.
10. SclabasGM,Staerkel GA, Vassillopoulou-Sellin R, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients.AmJ Surg 2003;186:702-709; discussion 709-710.
11. Cooper DS, DohertyGM,HaugenBR, et al.Managementguidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16: 109-142.
12. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111: 508-516.
13. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092- 2098.
14. Cantara S, Capezzone M, Marchisotta S, et al. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95: 1365-1369.
15. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol. 2010;118: 17-23.
16. Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010;34: 2589-2594.
17. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010;95(12): 5296-5304.
18. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.NEngl J Med. 2012;367: 705-715.
19. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12: 852-855.
20. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11: 31-46.
21. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32: 177-195.
22. Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 2011;136: 527-539.
23. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11: 685-696.
24. Beadling C, Neff TL, Heinrich MC, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 2013;15: 171-176.
25. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30: 216-222.
26. Kimura ET, NikiforovaMN,Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454-1457.
27. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/ PTCrearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22: 4578-4580.
28. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23: 7436-7440.
29. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88: 2318-2326.
30. Garcia-Rostan G, CostaAM,Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65: 10199-10207.
31. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93: 278-284.
32. HouP, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13: 1161-1170.
33. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in theCowdendisease gene,PTEN,in sporadic thyroid tumors. Cancer Res. 1997;57: 4710-4713.
34. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69: 4885-4893.
35. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6: 292-306.
36. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27: 535-560.
37. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:E863-E868.
38. Garcia-Jimenez C, Santisteban P. TSH signalling and cancer. Arq Bras Endocrinol Metab. 2007;51: 654-671.
39. sα mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J. 2009;56: 791-798.
40. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
41. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96: 3390-3397.
42. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452-W457.
43. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4: 1073-1081.
44. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7: 248-249.
45. Pang B, Durso MB, Hamilton RL, Nikiforova MN. A novel COLDPCR/ FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas. Diagn Mol Pathol. 2013;22: 28-34.
46. Whitehall V, Tran K,UmapathyA, et al.Amulticenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11: 543-552.
47. Nikiforov YE, NikiforovaMN.Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7: 569-580.
48. XingM.Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13: 184-199.
49. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945-D950.
50. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120: 71-77.
51. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91: 179-184.
52. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 1993;91: 1753-1760.
53. Dobashi Y, Sugimura H, Sakamoto A, et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol. 1994;3: 9-14.
54. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992;52: 1369-1371.
55. Ho YS, Tseng SC, Chin TY, Hsieh LL, Lin JD. p53 gene mutation in thyroid carcinoma. Cancer Lett. 1996;103: 57-63.
56. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93:3106- 3116.
57. Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97: 517-524.
58. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15: 1069-1074.